SkinMedica Receives FDA Approval For Dermatitis Treatment

SkinMedica Receives FDA Approval
Pharmaceutical company SkinMedica Inc. announced Oct. 23 that the company’s new drug application has received approval from the U.S. Food and Drug Administration, allowing SkinMedica to take another step forward into a billion dollar market.
SkinMedica’s dermatologic gel Desonate — created in partnership with Dow Pharmaceutical Sciences — is a corticosteroid treatment that helps improve the appearance of skin affected by atopic dermatitis.
Atopic dermatitis affects more than 15 million people and gives patients itchy skin, leading to rash, redness, swelling and scaling.
Steroids are considered the best treatment for atopic dermatitis and more than $1 billion in prescriptions are written annually by physicians in the United States for the treatment of inflammatory dermatoses.
Carlsbad-based SkinMedica specializes in developing dermatological products to improve the appearance of skin.
— Andy Killion